The establishment of ELISA-based measurements of Tau and Aβ in AD in the mid 1990s provided new approaches for the diagnostics of neurodegenerative dementia [9,10] and the possibility to detect especially AD already in the MCI phase [110,111]. The gene discussed is MAPT; the disease is Alzheimer disease.